Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer

Patent metadata

Field	Value
Publication number	US-9726670-B2
Application number	US-45203408-A
Country	US
Kind code	B2
Filing date	Jul 10, 2008
Priority date	Jul 19, 2007
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

First claim

The invention claimed is:

1. A method comprising:
assaying amounts of Liver Fatty Acid-Binding Protein (L-FABP), Carcinoembryonic Antigen (CEA), and Carbohydrate Antigen 19.9 (CA 19-9) in a biological fluid sample from a person suspected of having colorectal cancer.

2. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed by a biochemical test or by mass spectrometry.

3. The method as claimed in claim 1 , further comprising assaying for at least one member selected from the group consisting of Leukocyte Elastase Inhibitor, Ezrin, Aminoacylase 1, Intestinal Fatty Acid-Binding Protein, Apolipoprotein AI, Apolipoprotein AII, and Galectin-3.

4. The method as claimed in claim 1 , further comprising assaying for at least one member selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Keratin type II Cytoskeletal 8, Keratin type I Cytoskeletal 18, Keratin type I Cytoskeletal 19, Epithelial-Cadherin, Villin, CA 242, CA 50, CA 72-2, Testosterone, TIMP-1, Cripto-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, methylated DNA in the blood, specific alterations in fecal DNA fragments, and fecal human hemoglobin.

5. The method as claimed in claim 1 , further comprising assaying for at least one member selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Epithelial-Cadherin, Testosterone, TIMP-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, and fecal human hemoglobin.

6. The method as claimed in claim 1 , further comprising assaying for Galectin-3.

7. The method as claimed in claim 1 , further comprising assaying for Apolipoprotein AI.

8. The method as claimed in claim 1 , further comprising assaying for Leukocyte Elastase Inhibitor.

9. The method as claimed in claim 1 , further comprising assaying for Leukocyte Elastase Inhibitor and Aminoacylase 1.

10. The method as claimed in claim 1 , further comprising assaying for Leukocyte Elastase Inhibitor, Aminoacylase 1, Beta2-Microglobulin, Proteasome 20S, PAP, and E-Cadherin.

11. The method as claimed in claim 1 , further comprising assaying for Leukocyte Elastase Inhibitor, Aminoacylase 1, Beta2-Microglobulin, Proteasome 20S, Galectin-3, and Apolipoprotein AI.

12. The method as claimed in claim 1 , wherein the biological fluid sample is a blood or serum sample.

13. The method as claimed in claim 1 , wherein the biological fluid sample is a stool sample.

14. The method as claimed in claim 1 , wherein the biological fluid sample is a urine sample.

15. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed by a biochemical test.

16. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed by an immunoassay.

17. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed by ELISA.

18. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed using antibodies specific for L-FABP, CEA, and CA 19-9.

19. The method as claimed in claim 1 , wherein L-FABP, CEA, and CA 19-9 are assayed using an automated device.

20. A method comprising:
assaying amounts of Liver Fatty Acid-Binding Protein (L-FABP), Carcinoembryonic Antigen (CEA), and Carbohydrate Antigen 19.9 (CA 19-9) in a biological fluid sample from a person suspected of having or having colorectal cancer.

21. The method as claimed in claim 20 , further comprising assaying for at least one member selected from the group consisting of Leukocyte Elastase Inhibitor, Ezrin, Aminoacylase 1, Intestinal Fatty Acid-Binding Protein, Apolipoprotein AI, Apolipoprotein AII, and Galectin-3.

22. The method as claimed in claim 20 , further comprising assaying for at least one member selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Keratin type II Cytoskeletal 8, Keratin type I Cytoskeletal 18, Keratin type I Cytoskeletal 19, Epithelial-Cadherin, Villin, CA 242, CA 50, CA 72-2, Testosterone, TIMP-1, Cripto-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, methylated DNA in the blood, specific alterations in fecal DNA fragments, and fecal human hemoglobin.

23. The method as claimed in claim 20 , further comprising assaying for at least one member selected from the group consisting of Beta2-Microglobulin, Proteasome 20S, L-Lactate Dehydrogenase Chain B, Calreticulin, Regenerating Islet-Derived Protein 3 Alpha, Tumor-Associated Calcium Signal Transducer 1, Epithelial-Cadherin, Testosterone, TIMP-1, Intelectin-1, Protein Disulfide Isomerase, Cytokeratin 20, Translationally-Controlled Tumor Protein, (Pro)defensin-A5, and fecal human hemoglobin.

24. The method as claimed in claim 20 , further comprising assaying for Galectin-3.

25. The method as claimed in claim 20 , further comprising assaying for Apolipoprotein AI.

26. The method as claimed in claim 20 , further comprising assaying for Leukocyte Elastase Inhibitor.

27. The method as claimed in claim 20 , further comprising assaying for Leukocyte Elastase Inhibitor and Aminoacylase 1.

28. The method as claimed in claim 20 , further comprising assaying for Leukocyte Elastase Inhibitor, Aminoacylase 1, Beta2-Microglobulin, Proteasome 20S, PAP, and E-Cadherin.

29. The method as claimed in claim 20 , further comprising assaying for Leukocyte Elastase Inhibitor, Aminoacylase 1, Beta2-Microglobulin, Proteasome 20S, Galectin-3, and Apolipoprotein AI.

30. The method as claimed in claim 20 , wherein the biological fluid sample is a blood or serum sample.

31. The method as claimed in claim 20 , wherein the biological fluid sample is a stool sample.

32. The method as claimed in claim 20 , wherein the biological fluid sample is a urine sample.

Assignees

• Ataman-Onal Yasemin
• Beaulieu Corinne
• Charrier Jean-Philippe
• Choquet-Kastylevsky Genevieve
• Pons Sylvie
• Rolland Dominique
• Biomerieux Sa

Inventors

• Ataman-Onal Yasemin
• Beaulieu Corinne
• Charrier Jean-Philippe
• Choquet-Kastylevsky Genevieve
• Pons Sylvie
• Rolland Dominique

Classifications

• G01N2333/70567

  Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors · CPC title

• G01N33/57535 Primary

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N33/57419 Primary

  Physics · mapped topic